Abstract 35P
Background
Chemotherapy-induced alopecia is one of the most distressing symptoms for cancer patients undergoing cytotoxic chemotherapy. In this prospective two-center study, the objectives were to determine the efficacy and toxicity of a scalp-cooling device in the prevention of alopecia associated with chemotherapy.
Methods
Breast cancer patients who were planning for (neo)adjuvant chemotherapy consisting of taxane- and/or anthracycline- based regimens, with or without anti-HER2 therapy were invited to participate. They underwent a scalp cooling system offered by the Orbis Paxman Hair Loss Prevention System. The following were measured during the study: extent of hair loss based on Dean score (score ranges 0-4; 0-2 score reflects hair loss of 50% or less) 4 weeks after the completion of all cycles of chemotherapy, as determined by patients and independent assessors. Adverse events (AEs), specifically alopecia and potential study-related AEs, were graded according to NCI CTCAE v4.0.
Results
52 patients were enrolled into the study. 6 patients were excluded due to subjects’ own request (3), abnormal thyroid function (2) and anaemia (1). Of the remaining 46 patients, 50% each had taxane-based and taxane-anthracycline-based regimens. 3 of the 46 patients did not undergo any assessments after enrolment, resulting in 43 being assessable for outcomes. The median age was 51.5 years. A Dean score of 0-2 for hair loss was reported by 30.2% of the patients and 32.6% of the assessors. Only 4 patients (8.7%) did not require wearing headcover during the study. Alopecia grading were: grade 0 (9.3%), grade 1 (23.3%) and grade 2 (67.4%). Potential study-related AEs included dizziness [grade 1 (11.6%); grade 2 (2.3%)], headaches [grade 1 (4.7%)], complaint of cooling [grade 1 92.3%)]; there were no grade 3 or above toxicities.
Conclusions
In contrast to previous reports, the current scalp cooling system provided a lower efficacy in preventing alopecia in breast cancer patients also undergoing chemotherapy.
Acknowledgement: The scalp cooling system was provided by Orbis Paxman Hair Loss Prevention System.
Clinical trial identification
NCT4630080.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract